Signals, Powered By EquityPandit
The US health regulator has provided its final approval to Cipla for lipid regulating Fenofibrate tablets.
Cipla has said in a BSE filing that the company “has received final approval for its abbreviated new drug application (ANDA) for Fenofibrate tablets USP 48mg and 145mg, from the United States Food and Drug Administration (USFDA).”
It added that the tablets are generic versions of AbbVie’s Tricor tablets.
